Where wearable studies actually fail
Validation is downstream of wear-time.
Koneksa's validation pipeline is a genuine strength, turning sensor data into regulatory-grade endpoints across respiratory, oncology, and neuro. But validation assumes the data arrived complete. In real studies the data is incomplete because participants stop wearing devices and sync failures go uncaught upstream. Koneksa's model relies on others for that execution. Delve owns it: signal QC plus concierge wear-time recovery in 120+ languages.
Bottom line: If you want a specialist biomarker-validation partner and you have capture and engagement handled, Koneksa is strong. If you want one platform that captures, protects, and validates wearable data with wear-time recovery built in, Delve is the better-fitting choice.
Where Koneksa and Delve genuinely overlap
At the capability level, both can support a modern wearable-enabled trial. Both typically offer:
- Validated digital biomarkers and regulatory-grade endpoints
- Respiratory, oncology, and neuro endpoint experience
- Multi-sensor digital measure development
- A focus on submission-ready, defensible data
The differences show up once you ask what happens when a participant stops wearing the device, when a sensor produces unusable data, or when an endpoint depends on validated algorithms across more than one device.
Side-by-side comparison
Koneksa vs Delve Health: capability comparison
The table reflects publicly documented positioning and standard delivery models for each platform. Specific configurations vary by contract.
| Capability | Koneksa | Delve Health |
|---|---|---|
| Signal quality & endpoint integrity | ||
| Validated digital-endpoint algorithms | Yes — validation pipeline | 70+ algorithms across 25+ devices |
| Data capture & device integration | Integrates sensor data | Owned, device-agnostic |
| Signal quality control / completeness | Analytics-level QC | Owned QC at capture |
| Wear-time recovery (human) | Relies on others | Concierge in 120+ languages |
| Human concierge patient support | No | 120+ languages built in |
| eCOA / ePRO included | Biomarker analytics focus | Fully configurable eCOA |
| Device logistics & provisioning | Partner-dependent | End-to-end across devices |
| Per-study completion accountability | Customer-driven | 92–98% documented per study |
| Compliance posture (HIPAA, GDPR, 21 CFR Part 11, GCP, ISO 27001) | Yes | Yes |
Why wearable-heavy studies pick Delve
Four reasons sponsors choose Delve when wearable endpoint integrity, wear-time, or retention is the deliverable — not the customer's problem to solve.
Completion is the deliverable
Delve publishes documented 92–98% per-study eCOA/ePRO completion ranges and up to 63% retention uplift in long-duration cohorts — platform-owned, not the customer's problem to solve.
Validated algorithms across many devices
70+ validated digital-endpoint algorithms across 25+ devices on one harmonized data layer that normalizes units, sampling rates, time bases, QC flags, and algorithm versions.
Signal quality, owned end-to-end
Signal quality control validates completeness, flags drift, and catches sync failures before data is lost — not discovered at database lock.
Humans recover wear-time
Concierge-as-a-Service in 120+ languages recovers participants before wear-time decays — proactive outreach, device troubleshooting, escalation.
Which platform fits your study
Choose the platform that fits your operating model
Choose Koneksa if…
- You want a dedicated digital-biomarker validation partner
- Your endpoints are respiratory, oncology, or neuro and need a validation pipeline
- You already have capture, wear-time, and engagement handled
- You want an analytics-led, validation-first engagement
Choose Delve Health if…
- You want capture, signal QC, and wear-time owned in one platform
- You need validated algorithms across many devices, not analysis alone
- You need human concierge wear-time recovery in 120+ languages
- You want eCOA, logistics, and analytics together
- You want documented per-study completion (92–98%)
Frequently asked questions
Questions sponsors ask when comparing Koneksa and Delve Health
Is Delve Health a Koneksa alternative?
Yes, with a different emphasis. Koneksa specializes in digital-biomarker validation and analytics. Delve owns the full chain: device-agnostic capture, signal quality control, validated algorithms, wear-time recovery, eCOA, and concierge. Teams that want one accountable platform for data quality and completion typically prefer Delve.
Why does wear-time matter for biomarker validation?
A validated biomarker still needs complete data. If participants stop wearing the device or sync fails, the analysis has gaps no matter how good the validation pipeline is. Delve protects the upstream data with signal QC and concierge wear-time recovery so the biomarker has complete input.
Does Koneksa provide human patient support and wear-time recovery?
Koneksa is analytics- and validation-led and generally relies on others for capture and patient execution. Delve includes Concierge-as-a-Service in 120+ languages that proactively recovers wear-time before data is lost.
Can Delve and a biomarker specialist coexist in a study?
Yes. Delve can own capture, QC, and wear-time while a specialist contributes validation, or Delve can run validated algorithms end-to-end. The deciding question is who is accountable for the data quality the validation depends on.
Which is better for respiratory, oncology, or neuro endpoints?
Both can support these areas. Koneksa offers a deep validation pipeline; Delve runs validated algorithms across many devices and adds the signal QC and wear-time execution that keep the endpoint data complete across the study.
Evaluating Delve against Koneksa?
Ask each vendor one question: what happens to your endpoint when a participant stops wearing the device? The answer tells you more than any device list.
Book a Platform Walkthrough